CanFite BioPharma For Profit
Can-Fite BioPharma is an Israeli biopharmaceutical company that specializes in the discovery and clinical development of small molecule drugs for oncology, inflammatory, and metabolic diseases. The company's platform technology uses the Gi protein associated A3 adenosine receptor (A3AR) as a therapeutic target, which is highly expressed in pathological body cells. Can-Fite's compounds bind with nM affinity to the A3AR and initiate de-regulation of the NF-kB and the Wnt signal transduction pathways resulting in anti-inflammatory and anti-cancer effects. The company has an advanced pipeline of proprietary drug candidates in Phase II and Phase III clinical development. Contact info: N/A.
%20.jpg)
Total Funding:
$51.4M
Headquarters:
Petah Tiqva, HaMerkaz, Israel
Funding Status:
IPO
Employee Number:
1-10
Estimated Revenue:
$1M to $10M
Investment Stage:
N/A
Last Funding Type:
Post-IPO Equity
Number Of Exists:
Post-IPO Equity
Technology:
Drug development
Investor Type:
Company
Investors Number:
4
Founded Date:
1994-01-01
Industry:
PharmTech